Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

78.58 +0.05 (+0.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,607,191
Open 78.69
Bid (Size) 78.58 (11)
Ask (Size) 79.35 (1)
Prev. Close 78.53
Today's Range 78.32 - 79.26
52wk Range 60.47 - 87.67
Shares Outstanding N/A
Dividend Yield 1.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
Via Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+14.88%
+14.88%
1 Month
-7.31%
-7.31%
3 Month
+0.03%
+0.03%
6 Month
+19.55%
+19.55%
1 Year
+17.86%
+17.86%

More News

Read More
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
From AstraZeneca
Via Business Wire
5 Oversold Stocks to Buy Right Now
Via MarketBeat
AstraZeneca Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
From AstraZeneca
Via Business Wire
Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push
Via Investor's Business Daily
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
Via Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
3 Market-Beating Stocks to Buy for Less Than $100
Via The Motley Fool
AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities
Via Benzinga
Topics Law Enforcement
Exposures Legal
Reasonable Growth, Debt Levels, and a High ROIC Make ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Appealing to Quality Investors.
Via Chartmill
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
From AstraZeneca
Via Business Wire
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.